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Abstract: Mycophenolate mofetil (MMF) has been used to treat myasthenia gravis (MG) for over 
10 years. MMF’s use in the MG population stems from its theoretical mechanism of action and 
the medical literature that supports its beneﬁ  t in MG patients. Recently, two large, double-blinded, 
placebo-controlled, randomized clinical trials were initiated to study the effectiveness of MMF for 
MG. One of these studies found no beneﬁ  t in taking MMF with 20 mg of prednisone as compared 
to taking prednisone alone, while the other study demonstrated no advantage in taking MMF 
against placebo during a 36-week prednisone taper. This article critically reviews the medical 
literature on MMF’s use in MG and suggests further research avenues on this topic.
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Introduction
Myasthenia gravis (MG) is an autoimmune disorder that affects the post-synaptic 
neuromuscular junction on skeletal muscle via autoantibody binding to the nicotinic ace-
tylcholine receptors (AChR Ab). Antibody binding directly disrupts transmission between 
nerve and muscle ﬁ  ber causing patients to experience ﬂ  uctuating, fatigable weakness. 
Frequently, symptoms such as dysarthria, dysphagia, ptosis, and diplopia may occur. 
Occasionally, patients with MG may experience what is known as a myasthenia crisis: a life-
threatening respiratory compromise secondary to bulbar and diaphragmatic weakness.
The diagnosis of MG is based on the history and clinical ﬁ  ndings; however, the 
presence of serum AChR Ab, a greater than 10% decrement during repetitive nerve 
stimulation, and an increased amount of jitter with single ﬁ  ber electromyography 
(SFEMG) helps to conﬁ  rm the diagnosis (Ciafaloni 2005).
The ideal treatment for MG should be affordable, applicable to all myasthenia patients, 
easily administered, 100% effective, and without adverse effects. Unfortunately, a therapy 
that meets all of these characteristics has yet to be discovered. While corticosteroids are 
the most commonly used therapy for MG, other immunosuppressing agents are also used: 
1) In cases where MG is refractory to corticosteroid treatment; 2) As steroid-sparing 
agents; and, 3) In cases where severe corticosteroid side effects occur.
Currently available immunomodulating medications have varying mechanisms of 
action and side effect proﬁ  les. Immunomodulating medications frequently used for 
MG include: azathioprine, cyclosporine, cyclophosphamide, tacrolimus, intravenous 
immunoglobulin (IVIG), plasma exchange (PLEX) and mycophenolate mofetil. 
Thymectomy has also been identiﬁ  ed as an immunomodulating therapy for MG, yet 
its true efﬁ  cacy has yet to be deﬁ  nitively proven. The debate on the optimal agent for 
long-term management of myasthenia is far from settled.
Mycophenolate mofetil
Mycophenolate mofetil (MMF) (CellCept®, Roche) is a synthesized pro-drug of myco-
phenolic acid that inhibits the immune system by preferentially depleting guanosine and Neuropsychiatric Disease and Treatment 2008:4(6) 1204
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deoxygunaosine on both T and B-lymphocyte lines (Allison 
and Eugui 2005). MMF is thought to selectively inhibit ino-
sine monophosphate dehydrogenase type II, an enzyme that 
facilitates the production of an intermediate metabolite of 
guanosine (Schneider-Gold et al 2006). Ultimately, MMF is 
able to reduce the proliferation of T and B-lymphocytes and 
affect antibody formation and cell-mediated responses. MMF 
also acts on the immune system by: 1) Reducing lymphocytic 
recruitment to inﬂ  ammation; 2) Limiting tissue-damaging 
nitric oxide; 3) Inhibiting the expression of adhesion 
molecules; 4) Reducing the secretion of tumor necrosis 
factor alpha; 5) Increasing the expression of interleukin-10; 
and, 6) Elevating the rate of lymphocytic apoptosis (Allison 
2005; Schneider-Gold et al 2006). Given the unique immu-
nosuppressive properties of MMF, it has been tried as a 
therapy for many autoimmune conditions including: lupus 
erythematosus, rheumatoid arthritis, systemic vasculitis, 
cerebral vasculitis, multiple sclerosis, MG, pemphigus 
vulgaris, psoriasis, inflammatory eye disease, Crohn’s 
disease, Wegener’s granulomatosis, dysimmune polyneurop-
athies, cluster headache, inﬂ  ammatory myopathies, and organ 
transplantation (Epinette et al 1987; Enk and Knop 1997; 
Larkin and Lightman 1999; Neurath et al 1999; Nowack 
et al 1999; Meriggioli et al 2003; Rozen 2004; Cahoon and 
Kockler 2006; Schneider-Gold et al 2006).
Unlike most other classes of immunosuppressant therapy, 
MMF is not known to frequently produce major organ toxicity 
(Ciafaloni et al 2001). This feature of MMF makes it a poten-
tially appealing therapy for MG. While cyclosporine and 
azathioprine may cause nephrotoxicity and hepatotoxicity 
respectively, these potentially severe side effects are rare to 
non-existent with MMF use (Lim et al 2007). MMF is also 
thought to have a lower rate of induced late malignancies than 
azathioprine and cyclophosphamide. In addition, compared 
with corticosteroids, MMF has fewer adverse effects on 
bone health, weight, cataract formation, and hypertension 
(Chaudhry et al 2001; Meriggioli et al 2003; Allison 2005).
The use of MMF does carry some risk. There is currently 
a FDA black box warning that indicates that the use of MMF 
may increase one’s susceptibility to infection, the development 
of lymphoma, and may increase the risk of pregnancy 
loss and congenital malformation in childbearing woman. 
The most common side effect of MMF is gastrointestinal 
intolerance (usually diarrhea), however, nausea, vomiting, 
headaches, bone marrow suppression, sepsis, hypertension, 
tremor, neoplasia, depression, teratogenicity and an 
increased risk of infection may occur (Chaudhry et al 2001; 
Amato and Griggs 2003; Draper 2008). In one study of MMF 
combined with cyclosporine and corticosteroids for the 
prevention of acute renal transplant rejection, it was found 
that the MMF group (taking MMF at 1 or 1.5 g twice a day) 
had higher incidences (compared to a placebo group) of gas-
trointestinal symptoms, leucopenia, anemia, pancytopenia, 
agranulocytosis, cytomegalovirus tissue invasive disease, 
herpes zoster, herpes simplex and squamous-cell carcinoma 
(European Mycophenolate Mofetil Cooperative Study 
Group 1995).
Some severe adverse effects have also been reported 
in MG patients taking MMF. These effects have included: 
chronic heart failure, primary CNS lymphoma, a West 
Nile virus infection, a severe depressive episode, and a 
papulosquamous psoriatic-like skin eruption (Meriggioli 
et al 2003; Levin et al 2005; Vernino et al 2005; Draper 
2008). Although the exact relationship between MMF 
and these adverse conditions has not been proven, close 
patient monitoring is certainly warranted for MG patients 
taking MMF.
The optimal dose of MMF for MG is also unknown. 
Typical dosing for neuromuscular disease ranges from 
1500 mg a day to 3000 mg a day divided into twice a day 
(bid) or 3 times a day dosing. MMF has a high absorption 
rate from the gut and is 97% protein bound (Schneider-Gold 
et al 2006) Although plasma levels do not typically need to 
be checked, it is recommended to monitor complete blood 
cell counts routinely given the potential for leucopenia, 
anemia, pancytopenia, and agranulocytosis. While there is 
no direct contraindication in using MMF in conjunction with 
azathioprine, this practice is generally discouraged given the 
similar mechanism of action of these two medications.
Review of MMF use for MG
Up until 2008, the medical literature has largely been 
in favor of MMF for MG. Numerous case reports, an 
open-label pilot study, retrospective and studies, and one 
small placebo-controlled trial have all suggested clinical 
beneﬁ  t. More recently, two double-blind, placebo-controlled, 
randomized clinical trials have produced less positive results. 
We will review the medical literature here.
To our knowledge, the ﬁ  rst reported use of MMF for 
refractory MG was described in 1998 (Hauser et al 1998). In 
this report, a 26-year-old woman with MG manifesting with 
bulbar symptoms, weakness, and frequent hospitalizations 
was started on MMF at 500 mg 3 times a day. This patient 
noted beneﬁ  ts 5 days after receiving therapy. Her therapies 
prior to MMF included a transternal thymectomy, azathioprine 
for 6 months (discontinued secondary to nausea), multiple Neuropsychiatric Disease and Treatment 2008:4(6) 1205
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plasma exchanges, IVIG (stopped due to nausea and syncope), 
10 sessions of 100 cGy total body irradiation, 6 years of 
cyclosporine, pyridostigmine, and oral steroids. At the time 
of MMF use, the patient was on cyclosporine (6 mg/kg/day), 
prednisone (1 mg/kg/day alternating with 2 mg/kg/day) and 
pyridostigmine (90 mg/day). Cyclosporine was discontinued 
at the same time MMF was started given an increase in the 
patient’s creatinine level. Beneﬁ  ts attributed to MMF at 15 
months were a resolution in the patient’s dysarthria, extremity 
weakness, shortness of breath, and a decrease in her hospital-
ization rate. In addition, while taking MMF, the patient was 
also able to reduce her pyridostigmine and prednisone dosages 
without adverse effects (Hauser et al 1998).
In 2000, a case report described the beneﬁ  ts of MMF in 
a woman with MG in her twenties (Meriggioli and Rowin 
2000). Like the aforementioned patient, this woman had 
previously undergone a thymectomy and had both bulbar 
and extremity weakness. At the time MMF was added, she 
was on a regimen consisting of cyclosporine (3.4 mg/kg/
day), prednisone (40 mg/day of alternate-day treatment), 
and pyridostigmine (360 mg/day). This patient had previ-
ously tried azathioprine, but had to discontinue it due to 
liver toxicity. After taking MMF for 3 weeks, this patient 
reported less fatigable weakness and after 11 months she was 
found to have improvement in her manual muscle testing 
and quantiﬁ  ed MG score. Her requirement for prednisone, 
cyclosporine, and pyridostigmine also decreased (Meriggioli 
and Rowin 2000).
Given the promising ﬁ  ndings of these case reports, 
in 2001, Ciafaloni et al (2001) published an open-label 
pilot study evaluating the use of MMF for MG. This study 
evaluated 12 patients between the ages of 18 and 80 with 
acquired MG. Enrolled patients had either refractory MG 
(to a regimen of prednisone and azathioprine or prednisone 
and cyclosporine) or they required additional medica-
tions after taking corticosteroids for eight months. MMF 
was given at a rate of 1 g every 12 hours for 6 months. 
The primary measures of efﬁ  cacy were a reduction in 
the quantiﬁ  ed MG (QMG) score and manual muscle test 
(MMT), or a reduction in corticosteroid dose for 3 months 
without worsening of QMG and MMT scores. Eleven of 
the 12 enrolled patients had a thymectomy 7 to 42 months 
prior to the study.
The results of this study revealed that 6 patients taking 
MMF had improved QMG and MMT scores while two 
patients taking MMF had signiﬁ  cant reductions in their 
required corticosteroid dose. Of the 12 patients, one 
demonstrated a worsening of both QMG and MMT scores. 
After 6 months, Wilcoxon signed-rank sum analysis 
demonstrated improvements in MMT, QMG, and activities 
of daily living compared with baseline (p = 0.023, 0.001, 
0.004) with treatment effects seen as early as two weeks. 
Single fiber EMG was also performed in this study 
population, but did not change with therapy. Some patients 
did experience side effects from MMF. Two patients 
developed a transient hand tremor and 2 patients were 
found to have a decreased hemoglobin level (although 
one was iron deﬁ  cient). With the exception of these four 
patients, MMF was found to be well tolerated and safe 
(Ciafaloni et al 2001).
In 2001, a retrospective analysis of the use of MMF (1 g 
twice a day) for neuromuscular diseases was reported by 
Chaudhry et al (2001). Of the patients studied, 32 had MG 
(15 of which had previously undergone a thymectomy). 
Efﬁ  cacy was deﬁ  ned as any improvement in functional status 
(including activities of daily living, ptosis, diplopia, facial 
weakness, bulbar weakness, arm abduction time, muscle 
strength, or FVC), or a reduction in the required dose of 
steroids by over 10 mg a day. Of the 32 MG patients, 22 had 
improvements in either functional status or prednisone 
requirement with a time to improvement ranging from 2 to 
12 months. Ten of the MG patients experienced no beneﬁ  t 
after 8 months of use. In a subanalysis, patients that showed a 
favorable response to therapy tended to have been diagnosed 
with MG for a much shorter time (a mean of 7.5 months 
versus 14 years). Only 3 patients had been taking MMF as 
their only therapy in this study; the rest were taking com-
binations of corticosteroids, azathioprine, cyclosporine-A, 
methotrexate, plasma exchange and iv immunoglobulin. 
Some side effects were attributed to MMF. Three patients 
taking MMF developed gastrointestinal side effects and 
one other developed a “depressed mood” while on therapy 
(Chaudhry et al 2001).
In 2001, MMF was also being studied for MG in 
Germany. Schenider et al reported its use in 2 patients with 
severe refractory MG and one patient with MG-polymyositis 
syndrome (Schneider et al 2001). Patients received 1.5 to 
2.0 g MMF daily. The ﬁ  rst patient with refractory MG had 
previously failed combination immunotherapy consisting of 
cyclosporine, methotrexate, azathioprine, plasma exchange, 
and oral corticosteroids. This patient was placed on MMF in 
combination with weekly plasma exchange and corticosteroid 
use. Weakness reportedly improved and the patient was able 
to discontinue corticosteroid use and plasma exchange within 
3 months of MMF initiation with no recorded relapses in the 
following 18 months.Neuropsychiatric Disease and Treatment 2008:4(6) 1206
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A second refractory MG patient also reported symptomatic 
remission while on MMF. This patient had previously 
failed a course of azathioprine and corticosteroids. He was 
subsequently given plasma exchange and started on MMF 
with remission achieved after 6 months.
The last patient carried the diagnosis of MG-polymyositis 
syndrome. After experiencing a minimal resolve of her 
symptoms with corticosteroids, azathioprine, cyclosporine, 
and plasma exchanges, the patient was given MMF in place of 
her azathioprine. While on these multiple agents, the patient 
experienced a resolve of her polymyositis symptoms within 
6 months and was able to completely discontinue the use 
of her corticosteroids after 14 months. While on MMF, this 
patient also developed a hemolytic anemia which responded 
to a MMF dose reduction of 2.0 g a day to 1.5 g a day.
In a retrospective analysis of the use of MMF in 85 MG 
patients (Meriggioli et al 2003), patients were included in 
the study if they: 1) Carried the diagnosis of MG; 2) Had 
been treated at one of two major university centers; and, 
3) Had taken MMF for at least 3 months within the period 
February 1999 to September 2002. A determination of 
efﬁ  cacy was based on the Myasthenia Gravis Foundation 
of America’s (MGFA) post-intervention status scale. Of the 
study participants, 48 patients had previously undergone a 
thymectomy, 62 were on corticosteroids, 11 were on cyclo-
sporine, 7 were on azathioprine, and 1 was on methotrexate. 
For all indications, 73% of patients showed improvement 
while 89% of patients taking MMF as the only therapy 
showed improvement. Eighty-one percent of patients 
improved with MMF as an adjunctive therapy; however, 
only 43% of patients with refractory MG improved with 
MMF. Thirty-six of the 62 patients taking simultaneous 
steroids were able to decrease their dose, and 57% of the 
patients taking pyridostigmine were able to taper this 
medication while on MMF. The mean time to patient 
reported improvement was 8.8 weeks with a maximal 
improvement seen at 26.7 weeks. Of the 85 patients 
evaluated, 2 worsened with therapy, 5 discontinued 
MMF secondary to side effects, and 23 patients had 1 or 
more side effects (the most common side effects being 
nausea, vomiting, diarrhea or an increased rate of infec-
tion). In addition, 1 patient developed an autoimmune 
granulocytopenia, 1 patient had West Nile virus, and 
1 patient with cardiac valve disease developed congestive 
heart failure while taking MMF (Meriggioli et al 2003).
In 2003, the ﬁ  rst double-blind, placebo controlled trial 
was performed to evaluate the effects of MMF (1 g twice a 
day) versus placebo in 14 symptomatic stable MG patients 
over a 5-month period (Meriggioli et al 2003). Study 
participants were required to have persistent daily symptoms 
of fatigable weakness involving the ocular, bulbar, or limb 
muscles. Patients who had taken azathioprine, who were 
pregnant, or who had purely ocular MG, severe bulbar MG 
or were in crisis were excluded from the study. Patients 
were also required to be on a stable dose of prednisone or 
cyclosporine and have a stable baseline QMG score prior to 
entry. The primary measure of efﬁ  cacy was a change in QMG 
score while on treatment. QMG improved in the MMF group 
by an average of 2.86 points compared with 0.29 for placebo; 
however, this result was not statistically signiﬁ  cant (p = 0.30). 
A statistically signiﬁ  cant change in SFEMG values was noted 
between groups (p = 0.03), suggesting its potential use as an 
early biomarker to evaluate response to treatment (Meriggioli 
and Rowin 2003). Changes in manual muscle testing and 
AChR Ab did not reach statistical signiﬁ  cance between the 
two groups. Patients in the MMF group had side effects that 
included: diarrhea (2 patients), insomnia (1 patient), and 
urinary tract infections (2 patients) (Meriggioli et al 2003).
Two years later, a 5-patient case series of Asian patients 
was published on the use of MMF as an adjunctive therapy 
for refractory MG (Prakash et al 2007). All 5 patients had 
moderate to severe myasthenia symptoms, and were on 
corticosteroids, azathioprine, and pyridostigmine at the 
time of MMF initiation (500 mg 3 times a day). Within 2 to 
4 months of MMF initiation, all patients demonstrated 
symptomatic improvement with maintained beneﬁ  ts rang-
ing from 11 to 24 months. In addition, all patients were 
able to reduce their corticosteroid dosage without any 
clinical relapse. With the exception of one patient who 
experienced initial nausea and diarrhea, no patient had any 
signiﬁ  cant side effects from the MMF during this study 
(Prakash et al 2007).
MMF has been proposed as an alternative therapy for 
MG in patients who experience signiﬁ  cant side effects from 
other therapies. In a reported case series, Lim et al (2007) 
demonstrated that MMF could be successfully substituted 
for cyclosporine in myasthenia patients with cyclosporine-
induced nephrotoxicity. Two of 3 patients who switched 
to MMF experienced no neurological worsening of their 
MG with marked improvement of renal function once off 
cyclosporine. A third patient experienced improved renal 
function, but had one signiﬁ  cant myasthenia exacerbation 
during MMF use (Lim et al 2007).
MM has also been studied in patients with purely ocular 
symptoms (ocular MG) (Chan 2008). In a prospective obser-
vational study, 31 patients with ocular MG and positive AChR Neuropsychiatric Disease and Treatment 2008:4(6) 1207
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Ab were identiﬁ  ed and evaluated. Each of these patients had 
been started on 40 to 60 mg of prednisone and MMF to a 
titrated dose of 1.0 g/day. Once ocular symptoms resolved, 
each patient’s prednisone dose was tapered over a four week 
span. Researchers found that 87% (27/31) patients were able 
to tolerate the MMF. Of this group, 93% (25/27) remained at 
(MGFA) class I for an average observation period of 4.2 years. 
Although there was no direct comparison group in this study, 
the rate of decompensation to generalized myasthenia was 
thought to be equal or lower than ocular myasthenia patients 
taking azathioprine and/or corticosteroids compared with a 
separate retrospective study (Sommer et al 1997; Chan 2008). 
Of the 4 patients who discontinued MMF during Chan’s study, 
3 cited persistent diarrhea while 1 discontinued the medication 
secondary to cost.
After much anticipation, in 2008 the results of 2 large 
scale, double-blind, placebo-controlled, randomized clinical 
trials were published which tested the efﬁ  cacy of MMF in 
MG (Sanders et al 2008; The Muscle Study Group 2008). 
The relatively surprising ﬁ  ndings from these studies have 
caused much discussion and deliberation in the neuromuscular 
community.
The ﬁ  rst of these studies was implemented by the Muscle 
Study Group (MSG) and was designed to compare the use of 
MMF in combination with prednisone (20 mg/day) versus 
prednisone (20 mg/day) alone for generalized MG (The Muscle 
Study Group 2008). This study was an investigator-initiated, 
prospective, multi-centered, randomized, double-masked, 
and controlled to compare 2 treatment options. To be 
enrolled, each patient had to be over 18 years, have positive 
AChR Ab, and have generalized MG of mild to moderate 
severity. Patients were excluded if they had previously used 
a non-corticosteroid immunomodulating agent, had a ﬂ  uc-
tuating pyridostigmine dosage 2 weeks before enrollment, 
had a previously diagnosed thymoma, had severe weakness 
or oropharyngeal/respiratory symptoms, had a thymectomy 
within 12 months, or if they had used corticosteroids, PLEX, 
or IVIG within 90 days before enrollment.
Eighty patients were randomized to receive either 1.25 g 
of MMF twice a day and prednisone (20 mg/day) or placebo 
and 20 mg/day of prednisone. Patients were followed for 
12 weeks then were given the option to take open-label MMF 
for an additional 6 months. The primary outcome variable 
was the total QMG score from baseline to 12 weeks with 
secondary outcome variables including the change in total 
myasthenia MMT score, change in MG activities of daily 
living score, change in forced vital capacity, and change in 
SF-36v2 score.
Results of this study found no difference between groups 
in the primary and secondary outcome measures. Side effects, 
such as diarrhea, abdominal cramping, nausea, and vomiting, 
were more common in the MMF group than the placebo 
group. Episodes of urinary tract infection and cellulites 
occurred in the MMF arm of the study, however, the rate of 
infection did not appear to be signiﬁ  cantly different between 
the two groups (The Muscle Study Group 2008).
The second study set out to assess the efﬁ  cacy, safety, 
and tolerability of MMF as a steroid-sparing agent in patients 
with MG (Sanders et al 2008). Similarly to its companion 
study, this study was prospective, randomized, multi-
centered, and double-blinded. One-hundred and seventy-six 
patients with generalized MG and elevated AChR Ab were 
treated with at least 4 weeks of prednisone (20 mg/day or 
greater) without additional immunosuppressive therapy 
before being randomized. Patients were then randomized 
to receive 36 weeks of prednisone and MMF at 2 g/day 
or prednisone and placebo. The primary endpoint was a 
composite measure deﬁ  ned as achievement of minimal 
manifestation or pharmacologic remission with reduction of 
corticosteroid dose on a set schedule (Sanders et al 2008). 
Secondary endpoints included quality-of-life scores, disease 
severity, and safety.
This study found that treatment with MMF was not 
superior to placebo during a steroid taper. There were no 
signiﬁ  cant differences in patient scores for QMG, SF-36, 
MG activities of daily living, or global assessment between 
the MMF and placebo groups. In addition, serious infections 
occurred more frequently in the MMF group (8.0%) 
compared with the placebo group (3.4%). One of these 
serious infections included a fatal pneumonia in a patient 
taking MMF. Headache was also more frequently recorded 
in the MMF group (12.5% versus 6.8%); however reports of 
worsening of MG was more frequent in the placebo (20.5%) 
versus the MMF (11.4%) group (Sanders et al 2008).
Discussion
The collection of past research on MMF’s role in MG 
treatment is neither exhaustive nor conclusive. Early reports 
and studies appear to hint at MMF’s efﬁ  cacy, while the 
latest placebo-controlled trials did not deﬁ  nitively prove its 
beneﬁ  t compared with placebo. Each of the above described 
articles is not without criticism. Early case reports are thought 
provoking but are subject to positive study bias. It is not 
known how many times MMF was previously used for MG 
without effect. Such “failures” are typically not submitted 
to or accepted by major publications. In addition, signiﬁ  cant Neuropsychiatric Disease and Treatment 2008:4(6) 1208
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confounding factors exist in many of the early publications. 
Most patients in these studies had a history of prior or 
coexisting treatments including corticosteroid use, azathio-
prine, cyclosporine, thymectomy, IVIG, pyridostigmine, or 
full body radiation. In many cases these therapies were being 
used or withdrawn during the evaluation period of MMF thus 
complicating the interpretation of results. In cases where a 
therapy had been discontinued prior to MMF use, it is pos-
sible that long term, or even delayed effects could have been 
inappropriately attributed to MMF. Likewise, it is possible 
that positive or negative interactions occurred between MMF 
and simultaneously used therapies. Unfortunately, none of 
the early studies were designed to evaluate such interfer-
ence effects.
Much scrutiny has been placed on the latest randomized 
clinical trials due to their relatively unexpected (and perhaps 
contradictory) ﬁ  ndings. Many clinicians and scientists have 
pondered how a medication that seemed so promising in 
preliminary reports could produce such a bland treatment 
response. Varied explanations have been proposed, such as 
criticisms on the: 1) Length of the studies; 2) Selected patient 
populations; 3) Concurrent use of prednisone; 4) Multicenter 
approach; and, 5) The primary efﬁ  cacy measures. Many 
clinicians have adamantly defended MMF’s use based on 
prior clinical experience while dismissing the results of the 
latest two clinical trials. The scientiﬁ  c and clinical com-
munities should be careful not to completely disregard the 
results of these latest two trials. Instead, these trials should 
be accepted for what they are: two pieces of evidence in a 
rich tapestry of knowledge on MMF’s use for MG.
In some aspects it is not overly surprising that the latest 
recorded effects of MMF in MG were negative. While the 
prior case reports and retrospective studies hinted at efﬁ  cacy, 
the only previous placebo-controlled trial (while underpow-
ered) did not demonstrate positive results (Meriggioli et al 
2003). In addition, it is possible that the latest clinical trials 
did not evaluate the myasthenia patients that would have 
experienced the greatest beneﬁ  t from taking MMF. While 
the Muscle Study Group’s trial was well planned, carefully 
executed, and adequately analyzed, it only addressed the 
question of MMF’s usefulness in a very small subpopulation 
of MG patients, over a very speciﬁ  c (and perhaps too short) 
time frame, in the context of both concurrent prednisone use 
and a speciﬁ  c (and perhaps understudied) primary endpoint. 
While some literature suggests the early efﬁ  cacy of MMF, 
the retrospective study of 85 patients reported a maximal 
objective beneﬁ  t only at an average of 26.7 weeks (Meriggioli 
et al 2003). It is possible that a separation in efﬁ  cacy would 
have been demonstrated had the trial been carried out for a 
longer period of time. Also, while quantiﬁ  able, few would 
argue that the QMG score is the perfect measure of therapy 
effectiveness. The MSG study was powered to detect a 
difference of 3 points on the QMG score between the two 
arms. It is difﬁ  cult to know for certain if this was the most 
appropriate clinical difference in which to base an outcome 
measure.
Likewise, there are similar limitations in the 2008 Sanders 
et al MMF clinical trial. As pointed out in their paper, it is 
possible that the results of their study were tempered by an 
overly rigorous deﬁ  nition of treatment response, a study 
period that was perhaps too short (36 weeks), the unexpected 
effectiveness of low dose prednisone (7.5 mg/day), and an 
inclusion criteria that favored mild disease, older patients, 
men, and longstanding disease (over 3 years) (Sanders et al 
2008). Like the Muscle Group’s study, the results of this trial 
should only be extrapolated to the select MG population that 
shares a proﬁ  le with those studied in this clinical trial.
Another possible explanation for the negative results of 
the 2008 clinical trials is that the beneﬁ  t of low dose pred-
nisone and MMF on moderately affected MG patients is not 
additive. MMF was not studied in isolation, but rather as an 
add-on therapy to prednisone. Further studies on the efﬁ  cacy 
of MMF as a monotherapy (against placebo) or as an add-on 
therapy to other non-steroid immunosuppressive therapies 
should be performed to address this hypothesis.
In the future, the use of MMF should be studied in a more 
generalizable myasthenia population. It is possible that the 
study populations in the negative clinical trials had such 
mild cases that an add-on medication would not produce any 
additional measurable beneﬁ  t. For this reason, MMF should 
also be studied in patients with more severe MG or with MG 
refractory to corticosteroid treatment alone.
Lastly, it should be noted that a large discrepancy exists in 
the end point selection in most of the above listed studies. It 
is likely that this variation in outcome measure selection has 
played a signiﬁ  cant role in the apparently conﬂ  icting results 
of the above literature. Continued work will be required to 
fully identify and validate the ideal clinical outcomes for 
measuring changes in patient-relevant MG symptoms during 
future clinical studies.
Based on the most recent studies, difﬁ  cult questions will 
soon be asked by the patients, insurance companies, and the 
public. The use of MMF for MG will likely be questioned. 
Physicians will have to decide on the best course of action for 
each individual patient based on what is currently available 
in the literature. Additional studies are required given the Neuropsychiatric Disease and Treatment 2008:4(6) 1209
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limitations of the last two negative clinical trials and the many 
unanswered questions regarding MMF’s use for MG.
Conclusions
Much work remains to determine MMF’s true place in 
MG management. Despite recent studies, questions still 
exist regarding MMF’s long-term efﬁ  cacy, optimal dose, 
optimal population of use, optimal length of use, beneﬁ  t as 
a combination therapy, and long-term safety proﬁ  le. These 
speciﬁ  c questions should be addressed via future prospective 
placebo-controlled studies.
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